Management of high-risk HPV-positive women for detection of cervical (pre)cancer

ABSTRACT Introduction: Primary HPV-testing has been shown to provide a superior detection of women at risk of cervical (pre)cancer compared to cytology-based screening. However, as most high-risk HPV infections are harmless, additional triage testing of HPV-positive women is necessary to identify those with cervical (pre)cancer. In this paper, we compare the performance, advantages and limitations of clinically relevant available triage strategies for HPV-positive women. Areas covered: Many different colposcopy triage strategies, comprising both microscopy-based and molecular (virus/host-related) markers, have been suggested: Pap cytology, p16/Ki-67 dual-stained cytology, HPV16/18 genotyping, viral DNA methylation and host cell DNA methylation. Literature search was limited to triage strategies that have achieved at least phase 2 of the five-phase framework for biomarker development and studies including large cohorts (≥100 hrHPV-positive women). Triage markers were stratified by sample type (cervical scrape, self-collected sample) and by study population (screening, non-attendee, referral). Expert commentary: At present, repeat Pap cytology and Pap cytology combined with HPV16/18 genotyping are the only triage strategies that have been robustly shown to be ready for implementation. Other strategies such as p16/Ki-67 dual-stained cytology and host cell DNA methylation analysis, with or without additional HPV16/18 genotyping, are attractive options for the near future.

[1]  H. Hollema,et al.  A four‐gene methylation marker panel as triage test in high‐risk human papillomavirus positive patients , 2012, International journal of cancer.

[2]  American society for colposcopy and cervical pathology. , 1997, Journal of lower genital tract disease.

[3]  P. Defossez,et al.  The role of methyl-binding proteins in chromatin organization and epigenome maintenance. , 2012, Briefings in functional genomics.

[4]  J. Berkhof,et al.  Combined CADM1/MAL Methylation and Cytology Testing for Colposcopy Triage of High-Risk HPV-Positive Women , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[5]  J. Berkhof,et al.  Primary hrHPV DNA Testing in Cervical Cancer Screening: How to Manage Screen-Positive Women? A POBASCAM Trial Substudy , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[6]  M. Schiffman,et al.  Interobserver reproducibility and accuracy of p16/Ki‐67 dual‐stain cytology in cervical cancer screening , 2014, Cancer cytopathology.

[7]  M. von Knebel Doeberitz.  New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. , 2002, European journal of cancer.

[8]  J. Baak,et al.  Evaluation of MIB-1-Positive Cell Clusters as a Diagnostic Marker for Cervical Intraepithelial Neoplasia , 2002, The American journal of surgical pathology.

[9]  E. Franco,et al.  HPV testing with cytology triage for cervical cancer screening in routine practice. , 2014, American journal of obstetrics and gynecology.

[10]  M S Pepe,et al.  Phases of biomarker development for early detection of cancer. , 2001, Journal of the National Cancer Institute.

[11]  Carpay Mem,et al.  Uitvoeringstoets wijziging bevolkingsonderzoek baarmoederhalskanker 2013 , 2013 .

[12]  H. Hollema,et al.  Discovery of new methylation markers to improve screening for cervical intraepithelial neoplasia grade 2/3 , 2016, Clinical Epigenetics.

[13]  M. Sherman,et al.  Detection of genomic amplification of the human telomerase gene (TERC) in cytologic specimens as a genetic test for the diagnosis of cervical dysplasia. , 2003, The American journal of pathology.

[14]  J. Berkhof,et al.  Comparing triage algorithms using HPV DNA genotyping, HPV E7 mRNA detection and cytology in high-risk HPV DNA-positive women. , 2015, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[15]  J. Dillner,et al.  Human Papillomavirus and Papanicolaou Tests to Screen for Cervical Cancer , 2008 .

[16]  Julian Peto,et al.  Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. , 2012, Vaccine.

[17]  A. Longatto-Filho,et al.  HPV DNA testing with cytology triage in cervical cancer screening: Influence of revealing HPV infection status , 2015, Cancer cytopathology.

[18]  Stephen D Walter,et al.  Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. , 2007, The New England journal of medicine.

[19]  Mariska Bierkens,et al.  CADM1 and MAL promoter methylation levels in hrHPV‐positive cervical scrapes increase proportional to degree and duration of underlying cervical disease , 2013, International journal of cancer.

[20]  J. Cuzick,et al.  Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. , 2012, The Lancet. Oncology.

[21]  I. Runnebaum,et al.  A Promising DNA Methylation Signature for the Triage of High-Risk Human Papillomavirus DNA-Positive Women , 2014, PloS one.

[22]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[23]  J. Berkhof,et al.  Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial. , 2014, The Lancet. Oncology.

[24]  S. Wacholder,et al.  Human Papillomavirus DNA Methylation as a Potential Biomarker for Cervical Cancer , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[25]  P. Giorgi Rossi,et al.  Use of Cytology, E6/E7 mRNA, and p16INK4a-Ki-67 to Define the Management of Human Papillomavirus (HPV)-Positive Women in Cervical Cancer Screening. , 2016, American journal of clinical pathology.

[26]  Y. Li,et al.  MicroRNA Detection in Cervical Exfoliated Cells as a Triage for Human Papillomavirus–Positive Women , 2014, Journal of the National Cancer Institute.

[27]  C. Larsson,et al.  Detection of genomic amplification of the human telomerase gene TERC, a potential marker for triage of women with HPV-positive, abnormal Pap smears. , 2009, The American journal of pathology.

[28]  H. Skomedal,et al.  High-Risk Human Papillomavirus (hrHPV) E6/E7 mRNA Testing by PreTect HPV-Proofer for Detection of Cervical High-Grade Intraepithelial Neoplasia and Cancer among hrHPV DNA-Positive Women with Normal Cytology , 2012, Journal of Clinical Microbiology.

[29]  I. Kristiansen,et al.  HPV mRNA tests for the detection of cervical intraepithelial neoplasia: a systematic review. , 2011, Gynecologic oncology.

[30]  F J Bruinsma,et al.  The risk of preterm birth following treatment for precancerous changes in the cervix: a systematic review and meta‐analysis , 2011, BJOG : an international journal of obstetrics and gynaecology.

[31]  C. Meijer,et al.  Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions , 2014, Nature Reviews Cancer.

[32]  B. Kong,et al.  JAM3 methylation status as a biomarker for diagnosis of preneoplastic and neoplastic lesions of the cervix , 2015, Oncotarget.

[33]  Roy Zhang,et al.  Performance of p16/Ki-67 Immunostaining to Detect Cervical Cancer Precursors in a Colposcopy Referral Population , 2012, Clinical Cancer Research.

[34]  S. Wilting,et al.  Molecular events leading to HPV-induced high grade neoplasia , 2016, Papillomavirus research.

[35]  N. Muñoz,et al.  Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. , 2010, The Lancet. Oncology.

[36]  J. Cuzick,et al.  Validation of a DNA methylation HPV triage classifier in a screening sample , 2016, International journal of cancer.

[37]  S. Wacholder,et al.  Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3. , 2012, Journal of the National Cancer Institute.

[38]  J. Berkhof,et al.  FAM19A4 methylation analysis in self-samples compared with cervical scrapes for detecting cervical (pre)cancer in HPV-positive women , 2016, British Journal of Cancer.

[39]  A. Renshaw,et al.  The Tahoe Study: bias in the interpretation of Papanicolaou test results when human papillomavirus status is known. , 2014, Archives of pathology & laboratory medicine.

[40]  P. Hillemanns,et al.  Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. , 2014, The Lancet. Oncology.

[41]  J. Cuzick,et al.  Overview of the European and North American studies on HPV testing in primary cervical cancer screening , 2006, International journal of cancer.

[42]  G. Koliopoulos,et al.  p16INK4a immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis , 2009 .

[43]  J. Cuzick,et al.  Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. , 2008, Journal of the National Cancer Institute.

[44]  M. Sherman,et al.  Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. , 2009, Gynecologic oncology.

[45]  J. Dillner,et al.  Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial , 2014, BMJ : British Medical Journal.

[46]  G. Colditz,et al.  Loop Electrosurgical Excision Procedure and Risk of Preterm Birth: A Systematic Review and Meta-analysis , 2014, Obstetrics and gynecology.

[47]  Y. Qiao,et al.  An Evaluation of Novel, Lower-Cost Molecular Screening Tests for Human Papillomavirus in Rural China , 2013, Cancer Prevention Research.

[48]  H. Dickinson,et al.  Surgery for cervical intraepithelial neoplasia. , 2013, The Cochrane database of systematic reviews.

[49]  M. Schiffman,et al.  p16/Ki-67 Dual Stain Cytology for Detection of Cervical Precancer in HPV-Positive Women. , 2015, Journal of the National Cancer Institute.

[50]  R. Alaghehbandan.  p16/Ki-67 Dual-Stain Cytology in the Triage of ASCUS and LSIL Papanicolaou Cytology: Results From the European Equivocal or Mildly Abnormal Papanicolaou Cytology Study , 2012 .

[51]  Diane Solomon,et al.  Risk assessment to guide the prevention of cervical cancer. , 2007, American journal of obstetrics and gynecology.

[52]  C. Meijer,et al.  CADM1, MAL and miR124-2 methylation analysis in cervical scrapes to detect cervical and endometrial cancer , 2014, Journal of Clinical Pathology.

[53]  Johannes Berkhof,et al.  HPV testing on self collected cervicovaginal lavage specimens as screening method for women who do not attend cervical screening: cohort study , 2010, BMJ : British Medical Journal.

[54]  M. Haran,et al.  Comparison of a self‐administered tampon ThinPrep test with conventional pap smears for cervical cytology , 2005, The Australian & New Zealand journal of obstetrics & gynaecology.

[55]  K. Polyak,et al.  Methylation‐specific digital karyotyping of HPV16E6E7‐expressing human keratinocytes identifies novel methylation events in cervical carcinogenesis , 2013, The Journal of pathology.

[56]  M. Schiffman,et al.  Triage of HPV positive women in cervical cancer screening. , 2016, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[57]  C. Bergeron,et al.  p16/ki‐67 dual‐stain cytology in the triage of ASCUS and LSIL Papanicolaou cytology , 2011, Cancer cytopathology.

[58]  J. Ordi,et al.  Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology. , 2011, Gynecologic oncology.

[59]  A. Östör,et al.  Natural history of cervical intraepithelial neoplasia: a critical review. , 1993, International Journal of Gynecological Pathology.

[60]  J. Berkhof,et al.  Follow-up of high-risk HPV positive women by combined cytology and bi-marker CADM1/MAL methylation analysis on cervical scrapes. , 2015, Gynecologic oncology.

[61]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[62]  P. Castle,et al.  Offering Self-Sampling Kits for HPV Testing to Reach Women Who Do Not Attend in the Regular Cervical Cancer Screening Program , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[63]  T. Iftner,et al.  Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. , 2010, Journal of the National Cancer Institute.

[64]  M. Boily,et al.  The impact of differential uptake of HPV vaccine by sexual risks on health inequalities: a model-based analysis. , 2013, Vaccine.

[65]  M. Grce,et al.  Methylated Host Cell Gene Promoters and Human Papillomavirus Type 16 and 18 Predicting Cervical Lesions and Cancer , 2015, PloS one.

[66]  C. Meijer,et al.  Reasons for non-attendance to cervical screening and preferences for HPV self-sampling in Dutch women. , 2014, Preventive medicine.

[67]  Y. Qiao,et al.  Lower cost strategies for triage of human papillomavirus DNA-positive women , 2013, International journal of cancer.

[68]  T. Wright,et al.  Amplification of the 3q chromosomal region as a specific marker in cervical cancer. , 2015, American journal of obstetrics and gynecology.

[69]  J. Berkhof,et al.  Comparing the performance of FAM19A4 methylation analysis, cytology and HPV16/18 genotyping for the detection of cervical (pre)cancer in high‐risk HPV‐positive women of a gynecologic outpatient population (COMETH study) , 2016, International journal of cancer.

[70]  S. Rosso,et al.  Informed Cytology for Triaging HPV-Positive Women: Substudy Nested in the NTCC Randomized Controlled Trial , 2015, Journal of the National Cancer Institute.

[71]  J. Berkhof,et al.  HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications , 2012, British Journal of Cancer.

[72]  J. Berkhof,et al.  Clinical Validation of the HPV-Risk Assay, a Novel Real-Time PCR Assay for Detection of High-Risk Human Papillomavirus DNA by Targeting the E7 Region , 2014, Journal of Clinical Microbiology.

[73]  B Romanowski,et al.  Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women , 2009, The Lancet.

[74]  J. Habbema,et al.  Nonattendance is still the main limitation for the effectiveness of screening for cervical cancer in the Netherlands , 2006, International journal of cancer.

[75]  Thomas C Wright,et al.  Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. , 2011, The Lancet. Oncology.

[76]  P. Snijders,et al.  Methylation status of the E2 binding sites of HPV16 in cervical lesions determined with the Luminex® xMAP™ system. , 2012, Virology.

[77]  S. Wacholder,et al.  HPV16 methyl‐haplotypes determined by a novel next‐generation sequencing method are associated with cervical precancer , 2015, International journal of cancer.

[78]  R. Verheijen,et al.  Incidence and survival rate of women with cervical cancer in the Greater Amsterdam area , 2003, British Journal of Cancer.

[79]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[80]  C. Meijer,et al.  Development of a multiplex methylation-specific PCR as candidate triage test for women with an HPV-positive cervical scrape , 2012, BMC Cancer.

[81]  M. Liberati,et al.  Clinical Role of the Detection of Human Telomerase RNA Component Gene Amplification by Fluorescence in situ Hybridization on Liquid-Based Cervical Samples: Comparison with Human Papillomavirus-DNA Testing and Histopathology , 2015, Acta Cytologica.

[82]  J. Berkhof,et al.  Validation of the FAM19A4/mir124-2 DNA methylation test for both lavage- and brush-based self-samples to detect cervical (pre)cancer in HPV-positive women , 2016, Gynecologic oncology.

[83]  J. Cuzick,et al.  A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. , 2015, The New England journal of medicine.

[84]  Henry C Kitchener,et al.  HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. , 2009, The Lancet. Oncology.

[85]  J. Berkhof,et al.  Methylation Analysis of the FAM19A4 Gene in Cervical Scrapes Is Highly Efficient in Detecting Cervical Carcinomas and Advanced CIN2/3 Lesions , 2014, Cancer Prevention Research.

[86]  C. Meijer,et al.  Primary screening for high risk HPV by home obtained cervicovaginal lavage is an alternative screening tool for unscreened women. , 2002, Journal of clinical pathology.

[87]  P. Snijders,et al.  The clinical value of HPV genotyping in triage of women with high‐risk‐HPV‐positive self‐samples , 2016, International journal of cancer.

[88]  E. Schuuring,et al.  DNA methylation analysis in self-sampled brush material as a triage test in hrHPV-positive women , 2014, British Journal of Cancer.

[89]  J. Berkhof,et al.  Evaluation of 14 triage strategies for HPV DNA‐positive women in population‐based cervical screening , 2012, International journal of cancer.

[90]  J. Berkhof,et al.  Methylation marker analysis and HPV16/18 genotyping in high-risk HPV positive self-sampled specimens to identify women with high grade CIN or cervical cancer. , 2014, Gynecologic oncology.

[91]  Peng Guan,et al.  Human papillomavirus types in 115,789 HPV‐positive women: A meta‐analysis from cervical infection to cancer , 2012, International journal of cancer.

[92]  N. Coleman,et al.  Pathogenesis of human papillomavirus‐associated mucosal disease , 2015, The Journal of pathology.

[93]  P. Snijders,et al.  Long-term protective effect of high-risk human papillomavirus testing in population-based cervical screening , 2005, British Journal of Cancer.

[94]  H. Hausen.  Papillomaviruses and cancer: from basic studies to clinical application , 2002, Nature Reviews Cancer.

[95]  H. Inoue,et al.  Usefulness of CINtec® PLUS p16INK4a/Ki-67 Double-Staining in Cytological Screening of Cervical Cancer , 2011, Acta Cytologica.

[96]  J. Davis,et al.  Cross‐sectional Study of Patient‐ and Physician‐Collected Cervical Cytology and Human Papillomavirus , 2003, Obstetrics and gynecology.

[97]  V. Popendikyte,et al.  Different DNA methylation pattern of HPV16, HPV18 and HPV51 genomes in asymptomatic HPV infection as compared to cervical neoplasia. , 2015, Virology.

[98]  R. Burk,et al.  Methylation of HPV16 genome CpG sites is associated with cervix precancer and cancer. , 2011, Gynecologic oncology.

[99]  J. T. Cox,et al.  Chapter 7: Achievements and limitations of cervical cytology screening. , 2006, Vaccine.

[100]  J. Cuzick,et al.  Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. , 2010, The Lancet. Oncology.

[101]  J. Doorbar,et al.  Human papillomavirus molecular biology and disease association , 2015, Reviews in medical virology.

[102]  J. Peto,et al.  The cervical cancer epidemic that screening has prevented in the UK , 2004, The Lancet.

[103]  G. Ronco,et al.  Trials comparing cytology with human papillomavirus screening. , 2009, The Lancet. Oncology.

[104]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[105]  Clare Gilham,et al.  Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials , 2014, The Lancet.

[106]  Evan R. Myers,et al.  Accuracy of the Papanicolaou Test in Screening for and Follow‐up of Cervical Cytologic Abnormalities: A Systematic Review , 2001 .

[107]  J. Berkhof,et al.  Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial , 2007, The Lancet.

[108]  K. Thai,et al.  Clinical Performance of Roche Cobas 4800 HPV Test , 2014, Journal of Clinical Microbiology.

[109]  C. Wheeler,et al.  Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial , 2006, The Lancet.

[110]  Holly Janes,et al.  Pivotal Evaluation of the Accuracy of a Biomarker Used for Classification or Prediction: Standards for Study Design , 2008, Journal of the National Cancer Institute.

[111]  J. Berkhof,et al.  Clinical progression of high-grade cervical intraepithelial neoplasia: estimating the time to preclinical cervical cancer from doubly censored national registry data. , 2013, American journal of epidemiology.

[112]  M. von Knebel Doeberitz,et al.  Screening for Cervical Cancer Precursors With p16/Ki-67 Dual-Stained Cytology: Results of the PALMS Study , 2013, Journal of the National Cancer Institute.

[113]  David R. Scott,et al.  The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. , 2005, Journal of the National Cancer Institute.

[114]  M. Sherman,et al.  Heterogeneity of high‐grade cervical intraepithelial neoplasia related to HPV16: Implications for natural history and management , 2013, International journal of cancer.

[115]  M. Schiffman,et al.  American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer , 2012, CA: a cancer journal for clinicians.

[116]  J. Berkhof,et al.  High Concordance of Results of Testing for Human Papillomavirus in Cervicovaginal Samples Collected by Two Methods, with Comparison of a Novel Self-Sampling Device to a Conventional Endocervical Brush , 2006, Journal of Clinical Microbiology.

[117]  M. Poljak,et al.  Nucleic acid tests for the detection of alpha human papillomaviruses. , 2012, Vaccine.

[118]  A. Sapino,et al.  Interpretation of p16INK4a/Ki‐67 dual immunostaining for the triage of human papillomavirus‐positive women by experts and nonexperts in cervical cytology , 2015, Cancer cytopathology.

[119]  A. Anttila,et al.  Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. , 2009, Journal of the National Cancer Institute.

[120]  Susanne Rehm,et al.  Prospective evaluation of p16/Ki‐67 dual‐stained cytology for managing women with abnormal Papanicolaou cytology: PALMS study results , 2015, Cancer cytopathology.

[121]  Charlotte Paul,et al.  Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. , 2008, The Lancet. Oncology.

[122]  J. Berkhof,et al.  p16/Ki-67 dual-stained cytology for detecting cervical (pre)cancer in a HPV-positive gynecologic outpatient population , 2016, Modern Pathology.